uniQure recent selloff overdone, says H.C. Wainwright

H.C. Wainwright says the selloff in shares of uniQure (QURE) tied concerns about the appointment of a new Center for Biologics Evaluation and Research head and Huntington’s disease competitor data is overdone. investors are concerned that both will weigh on the FDA’s decision to grant accelerated pathway to approval for AMT-130, uniQure’s lead gene therapy candidate for the treatment of Huntington’s disease, the analyst tells investors in a research note. However, citing AMT-130’s “strong data” and “nothing-but-positive feedback” from key opinion leaders on uniQure’s program, the firm continues to expect a positive outcome from the regulatory interactions with the FDA in Q2. H.C. Wainwright reiterates a Buy rating on the shares with a $70 price target uniQure is a HCW top pick for 2025.